Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) COO Sells $1,519,049.70 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 16,515 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $1,519,049.70. Following the completion of the sale, the chief operating officer directly owned 40,272 shares of the company’s stock, valued at $3,704,218.56. The trade was a 29.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Peter Radovich also recently made the following trade(s):

• On Monday, February 2nd, Peter Radovich sold 2,631 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $103.30, for a total transaction of $271,782.30.
• On Monday, January 26th, Peter Radovich sold 3,143 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $96.19, for a total transaction of $302,325.17.
• On Thursday, January 22nd, Peter Radovich sold 2,382 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.33, for a total transaction of $222,312.06.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock opened at $90.72 on Friday. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.67 and a quick ratio of 2.55. The firm has a 50-day moving average of $96.51 and a 200-day moving average of $81.14. Mirum Pharmaceuticals, Inc. has a one year low of $36.88 and a one year high of $109.28. The company has a market cap of $5.47 billion, a P/E ratio of -189.00 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The firm had revenue of $148.93 million for the quarter, compared to analysts’ expectations of $141.78 million. During the same quarter last year, the firm posted $1.00 earnings per share. The firm’s revenue for the quarter was up 49.8% compared to the same quarter last year. Equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on MIRM. Royal Bank Of Canada cut their target price on Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating on the stock in a research note on Thursday, February 26th. Robert W. Baird lifted their price target on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. Evercore set a $126.00 price objective on Mirum Pharmaceuticals in a research note on Wednesday, March 4th. Finally, Morgan Stanley raised their target price on Mirum Pharmaceuticals from $95.00 to $123.00 and gave the company an “overweight” rating in a research report on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $117.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of MIRM. Emerald Advisers LLC grew its stake in shares of Mirum Pharmaceuticals by 20.9% during the 3rd quarter. Emerald Advisers LLC now owns 369,600 shares of the company’s stock worth $27,095,000 after acquiring an additional 63,834 shares during the period. Candriam S.C.A. raised its stake in Mirum Pharmaceuticals by 8.0% in the 3rd quarter. Candriam S.C.A. now owns 403,026 shares of the company’s stock valued at $29,546,000 after acquiring an additional 30,021 shares during the period. TimesSquare Capital Management LLC bought a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at about $22,041,000. Y Intercept Hong Kong Ltd purchased a new stake in Mirum Pharmaceuticals during the third quarter valued at about $808,000. Finally, Baader Bank Aktiengesellschaft purchased a new stake in Mirum Pharmaceuticals during the third quarter valued at about $503,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.